Is the pill as good as the shot?
The pill has caught the first shot, not the best shot. Oral semaglutide, at about 11% of body weight lost, now matches Wegovy, the roughly 12% injection that opened the era. But the best injections stay well ahead and injection only: tirzepatide (Zepbound) is about half again as much, at 18%, and retatrutide’s early Phase 3 topline points higher still, about 21%, not yet peer reviewed.
Where the oral-vs-injectable race stands, as of mid-2026.Three questions, not one
magnitude, tolerability, and the trade-offDoes it lose as much weight?
The one objective cross-route comparison. Weight lost is weight lost, whether from a pill or a shot, so both go on one scale.
Will you actually lose it?
Whether you can stay on the drug, and whether the headline number already counts the people who could not. How gentle it is depends on the drug, not on whether it is a pill.
Which should you pick?
A needle for a few more points, or a pill to skip the needle. Only you can price that trade, so it is the one we leave to you.
Weight loss can be compared across routes. A grade cannot.
Q1 · On the scale
every drug, one shared magnitude axisEvery figure is placebo-adjusted (the drug’s result minus the placebo group’s) and uses the treatment-policy or treatment-regimen estimate. It asks for the average effect of assignment regardless of treatment discontinuation and other changes specified in the trial’s analysis plan. The full method is on the methodology page.
Letters grade within route: the best pill and the best shot both earn an A. The bar is the magnitude; the letter is not a cross-route rank.
Part molecule, part delivery
Not because pills are weak. The strongest weight loss today needs a multi-agonist peptide, and peptides are hard to absorb from the gut. The orals come in two kinds, and neither has closed the gap. The peptides pushed across the gut with an absorption enhancer, like oral semaglutide and oral amycretin, come with a strict empty-stomach routine and have topped out near 12% so far. The small molecules furthest along, orforglipron and aleniglipron, carry no such rule but hit GLP-1 and nothing else.
Closing the gap needs an advance, not just time
Frontier efficacy in a clean pill needs more than one target, and a small-molecule dual or triple has no disclosed clinical candidate as of mid-2026. The nearest route on offer is a combination rather than one molecule: Structure’s oral small-molecule amylin drug entered Phase 1 in December 2025 and is built to be taken with a GLP-1. An unapproved 50 mg oral dose of semaglutide reaches about parity with the Wegovy injection in trials, but that is the first shot, not the best one, and the board scores the approved 25 mg anyway. So the pill catching the best shot is not a matter of waiting; nothing that exists today does it.
Q2 · In real life
how well you tolerate it depends on the drugHow well you tolerate a drug depends on the drug, not on whether it is a pill or a shot. Counting the people who quit, the extra dropout over placebo runs about 1 percent for oral semaglutide, 4 for the Wegovy injection, and 8 for orforglipron, another pill. So which pill you take matters more than the fact that it is a pill.
Q3 · For you
the one we will not scoreThe trade between a few more points of weight loss and never taking a needle is yours to weigh, so this is the question we hand back to you. Here is what differs once you have the numbers.
Most weight loss, needle and cold chain
Subcutaneous injection, once weekly. Storage: refrigerated (room temperature up to 28 days). The most weight loss, at the cost of an injection and keeping it cold.
Injection-class loss, a fasting routine
Oral pill, once daily, room temperature. The catch: must take fasting: empty stomach, limited water, wait before eating. No needle and no cold chain, but a daily routine you have to keep.
Fewest rules, less loss so far
Oral pill, once daily, no food or water restriction, room temperature, and a scalable small-molecule supply. It trails the peptide pill on the scale; its case is convenience.
The specific head-to-heads: oral semaglutide vs orforglipron, orforglipron vs Wegovy, and the same molecule two ways, oral vs injectable semaglutide.
What would change the answer
what we are watching forThe answer changes when a pill matches an injection for weight loss on a schedule people can keep. Two kinds of pill are chasing it, and they are chasing it in different ways.
The oral peptides on the watchlist: Amycretin and VK2735. A peptide is the same kind of molecule as the injection and just as hard to absorb, so it needs an enhancer to get across the gut, and the enhancer is what brings the empty stomach and the plain water. Viking has not disclosed an enhancer or a food rule for VK2735.
The oral small molecules on the watchlist: Aleniglipron. These carry no food rule, and the assumption has been that they pay for it on the scale. On the board they still do: orforglipron, the only small molecule to finish Phase 3, came in below the peptide pill. Aleniglipron is the first sign that the trade may not be permanent, though its evidence is still Phase 2 and not the 68-week window the board scores. What has not changed is the target count. Every small-molecule pill that has reached late-stage obesity trials hits GLP-1 and nothing else, while the strongest injections hit two or three. The first attempt to break that is now in the clinic: Structure’s oral small-molecule amylin drug, ACCG-2671, began Phase 1 in December 2025 and is designed to be taken with a GLP-1. It is early, and the combination evidence so far is preclinical. The day a pill posts injection-class weight loss in Phase 3, the answer here changes.